While these studies underscore the importance of NADPH oxidase in cardiac hypertrophy and heart failure, it is noteworthy that ROS from enzymatic sources can modulate or trigger the activity of other ROS sources [48,49,50]. The gene discussed is FMO5; the disease is cardiac hypertrophy.